Clinical trials: IV Injection
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
PONV
US Phase III Study of APD421 in PONV
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT01991860
- Testing
- APD421- Amisulpride for IV injection
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- Acacia Pharma Ltd
Parathyroid Hormone
Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis
This is the post-marketing study conducted in two countries: Croatia and Serbia. In both countries Zemplar (paricalcitol) is the first injectable form of any Vitamin D Receptor (VDR) activator available for chronic kidney disease…
- Trial name
- NCT01084538
- Testing
- Zemplar iv (paricalcitol iv)
- Where
- 21 sites in Croatia, Serbia
- Volunteers
- 181 people
- Sponsor
- Abbott
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with…
- Trial name
- EPITOME-1 (NCT01105091)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Volunteers
- 30 people
- Sponsor
- Actelion
Osteoarthritis, Knee, Knee Degenerative Disease
Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells
In this prospective study we aim to evaluate the feasibility and safety of the implantation of 40 millions MSV in knees with osteoarthritis of grade II-IV (Kellgren and Lawrence).
- Conditions
- Osteoarthritis, Knee, Knee Degenerative Disease, Knee Osteoarthritis
- Trial name
- KDD&MSV (NCT01183728)
- Testing
- Autologous bone marrow mesenchymal stem cells (MSV)
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Red de Terapia Celular
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety
This is a Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study. The primary objective was assessed by the difference in the mean number of ranibizumab injections applied up to Month 11 between the 2…
- Trial name
- ZIPANGU (NCT02953938)
- Testing
- Ranibizumab, Grid&Direct short pulse laser photocoagulation
- Where
- 7 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers
BCD-066 is a darbepoetin alfa. Clinical study BCD-066-3 is a double-blind controlled, randomized, parallel-group study of the pharmacokinetics, pharmacodynamics, tolerability, and safety of multiple intravenous injections of…
- Trial name
- NCT03693950
- Testing
- BCD-066, Aranesp
- Where
- Russia
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Biocad
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
HIV-1-infection
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push" or intramuscular injection.
- Trial name
- NCT03913195
- Testing
- ibalizumab-uiyk
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Respiratory Tract Infections, Urinary Tract Infections
Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the…
- Trial name
- SWSB (NCT01426191)
- Testing
- xinzhijun
- Volunteers
- 2,032 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Central Nervous System Pathology
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug…
- Trial name
- NCT04307186
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
- Where
- 17 sites in United States, Bulgaria and 2 more
- Volunteers
- 57 people
- Sponsor
- Bayer
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
- Trial name
- NCT00683332
- Testing
- Tigecycline (Tygacil)
- Where
- Philippines
- Volunteers
- 621 people
- Sponsor
- Pfizer
Neovascular Age-related Macular Degeneration
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
- Trial name
- SALT (NCT01958918)
- Testing
- Ranibizumab, Aflibercept
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 712 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and safety of BCD-066 (darbepoetin alfa manufactured by CJSC BIOCAD, Russia) and Aranesp® (Amgen Europe B.V., Netherlands) in healthy…
- Trial name
- NCT02506881
- Testing
- Darbepoetin alfa
- Where
- Russia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biocad
Hemophilia A
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.
- Trial name
- NCT03205163
- Testing
- Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose)
- Where
- 10 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bioverativ, a Sanofi company
Acute Urticaria
Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria
This is a multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36…
- Trial name
- NCT02023164
- Testing
- JDP-205 Injection, Diphenhydramine
- Where
- 6 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- JDP Therapeutics, Inc.
Osteoarthritis of the Knee
Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee
The main objective is the long-term comparison (3 years and 4 months) of the efficacy and safety of repeated intra-articular administration of hyaluronic acid in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00669032
- Testing
- Hyaluronic acid
- Volunteers
- 446 people
- Sponsor
- Tedec-Meiji Farma, S.A.
Neoplasms
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); To assess safety and anti-tumour efficacy and determine pharmacokinetic…
- Trial name
- NCT01214616
- Testing
- afatinib 20mg, afatinib 40mg, vinorelbine IV 25 or 20mg/m2
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim